|
The shingles vaccine has two types of vaccines: Zostavax and SkyZoster, which have weakened live chickenpox viruses. However, these vaccines have the disadvantage that their protective effect decreases rapidly with age, and they cannot be given to people with weakened immune systems.
To address these shortcomings, a private vaccine called Shingrix has been developed, which is an adjuvant attached to a part of the virus. Shingrix is highly effective in preventing shingles in people in their 5-60s by nearly 97% and in people in their 70s and above, with a level of 91%. More importantly, it can be given to people who are immunocompromised, and it can also prevent postherpetic neuralgia. It is also reported to be effective for up to 9 years.
Existing vaccines such as Zostavax and SkyZoster use live viruses, but Shingrix contains only a fraction of the virus, making it much safer to administer. But instead of being safe, there's a problem. Because the virus is not alive, you need to get two shots to trigger an immune response.
After the first vaccination, you should get another vaccination with an interval of 2~6 months, and if you are immunocompromised, it is okay to take an interval of 1~2 months.
Shingrix is available to anyone over the age of 50 (or 18 years of age or older if immunocompromised), regardless of whether they have had herpes zoster, received other herpes zoster vaccinations, or have antibodies.
The previous vaccine was a live virus, so I couldn't get an injection during chemotherapy. However, Shingrix can be vaccinated during chemotherapy, and it can be given to those who are breastfeeding, except for pregnant women.
Comments (0)
There are no comments for this article. Be the first one to leave a message!